Though ovarian cancer ranks seventh in the list of the most common types of cancers worldwide, its affliction rate continues to rise. These are the estimates of the World Cancer Research Fund International, which also states that the prevalence of this disease remarkably higher in less developed countries. The Asia Pacific market has not only seen a rise in the number of ovarian cancer cases reported annually, but has also been a fertile playground for several new therapies to be developed.
Within Asia Pacific, countries where ovarian cancer pipelines are most active are: China, India, Japan and Australia. Even as this market continues to thrive and grow at a steady pace, a recent market report by GBI research carries some interesting trends. These are:
· The Asia Pacific ovarian cancer therapies market features a white space for maintenance therapies. At present, the most widely used type of chemotherapy is the platinum-based one. The use of paclitaxel and carboplatin chemotherapy regimen is seen to be the most commonly-used one. Data shows that this is the most widely used standard of care for treating platinum-sensitive ovarian cancer in both first-line as well as recurrent cases. As the efficacy of the initial treatment is seen to be satisfactory, the remission rates continue to remain above acceptable levels. However, studies also show that nearly all patients with relapse (after they have been through remission and relapse) either succumb to ovarian cancer or develop platinum-resistant ovarian cancer.
· The prognosis for platinum-resistant ovarian cancer is currently poor, and leaves a wide gap where companies can fill with innovative solutions. Thus, the demand for maintenance therapies is high in the Asia Pacific ovarian cancer market. Moreover, the time is right for market players to invest in developing more effective treatment solutions for patients that are afflicted with platinum-sensitive ovarian cancer.
· Approvals for olaparib and trebananib, two promising drug candidates for the treatment of ovarian cancer, are expected to come through before 2020. But even after being approved, their penetration rates will remain somewhat restricted to the surface of the ovarian cancer market. Currently, the ovarian cancer therapeutics pipeline is rather crowded, but it still leaves a lot to be desired on the efficacy of late-stage drugs. Only minimal improvements have been observed in progression-free survival rates.
Browse the full Press Release of Ovarian Cancer Market : http://www.mrrse.com/ovarian-cancer-therapeutics-market-report
Based on the factors discussed above, it can be said that the ovarian cancer market in Asia Pacific will not be driven by new drug approvals. Growth will primarily be a result of inflation and the general rise in the prevalence rates of ovarian cancer. On the positive side, the large number of drug candidates in the ovarian cancer pipeline will keep the industry’s interest levels and degree of competition moderately high.